Favorable outcomes of tacrolimus compared with cyclosporine A for GVHD prophylaxis in HSCT for standard-risk hematological diseases

A Proportional Hazards Model for the Subdistribution of a Competing Risk

Jason P. Fine · Journal of the American Statistical Association · 1999 · 13.6K citations

Public Health, Biostatistics, Cost-effectiveness Analysis +15

Risk factors for acute GVHD and survival after hematopoietic cell transplantation

Madan Jagasia, Mukta Arora, Mary E.D. Flowers et al. · Blood · 2011 · 697 citations

Medicine, Hematology, Immunology +16

Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.

Richard A. Nash, Joseph H. Antin, Chatchada Karanes et al. · PubMed · 2000 · 591 citations

Life Sciences, Hematology, Immunology +13

Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.

Voravit Ratanatharathorn, Richard A. Nash, Donna Przepiorka et al. · PubMed · 1998 · 568 citations

Life Sciences, Immunology, Pharmacology +16

Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial

Rainer Storb, H. Joachim Deeg, M. S. Pepe et al. · Blood · 1989 · 432 citations · Full text

Life Sciences, Hematology, Immunology +16